Trial Profile
A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 07 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 08 Mar 2012 Substudy results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 13 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.